Datameds AI Inc (MEDS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MEDS SEC filings page.
Datameds AI Inc (MEDS) reported $8.0M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is offsetting operating cash needs while sharply higher costs have turned modest revenue growth into a gross loss.
Revenue reached$23.3M in FY2025, but gross margin turned negative at-27.5% from a positive FY2024 level; incremental sales did not cover direct costs. SG&A expanded to$70.3M , pushing operating margin to-401.7% ; the loss therefore reflects both negative gross economics and an unusually heavy overhead load.
Operating cash outflow widened from
Shares outstanding roughly doubled to 104.9M shares from 51.9M shares, indicating that the funding mix included substantial equity issuance. Liquidity is extremely tight: the current ratio was 0.1x, while FY2025 total liabilities exceeded total assets and equity was negative. The balance sheet is therefore constrained by solvency as well as short-term liquidity.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Datameds AI Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Datameds AI Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Datameds AI Inc's revenue surged 28.7% year-over-year to $23.3M, reflecting rapid business expansion. This strong growth earns a score of 89/100.
Datameds AI Inc's current ratio of 0.09 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Not available for Datameds AI Inc, and counted as zero in the overall score.
Datameds AI Inc scores -15.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.9M) relative to total liabilities ($42.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Datameds AI Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Datameds AI Inc reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Datameds AI Inc reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Datameds AI Inc generated $1.8M in revenue in Q2 2026. This represents a decrease of 77.2% from the same quarter a year earlier. Against the prior quarter it is up 14.1%.
Datameds AI Inc's EBITDA was -$7.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 48.8% from the same quarter a year earlier. Against the prior quarter it is down 23.5%.
Datameds AI Inc reported -$18.4M in net income in Q2 2026. This represents a decrease of 175.2% from the same quarter a year earlier. Against the prior quarter it is down 137.2%.
Cash & Balance Sheet
Datameds AI Inc held $2.5M in cash against $12.6M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Datameds AI Inc's gross margin was 10.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
MEDS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M-77.2% | $1.6M-85.6% | $1.7M | $3.0M-46.9% | $7.8M+17391.8% | $10.9M | N/A | $5.7M |
| Cost of Revenue | $1.6M-78.1% | $1.4M-86.3% | $9.5M | $2.8M-46.0% | $7.3M+15351.6% | $10.2M | N/A | $5.2M |
| Gross Profit | $182K-64.0% | $170K-75.4% | -$7.9M | $231K-55.7% | $506K+19492.3% | $693K | N/A | $521K |
| SG&A Expenses | $7.1M+45.2% | $4.9M-84.4% | $4.1M | $30.2M+1577.5% | $4.9M+752.0% | $31.2M+38981.4% | N/A | $1.8M |
| Operating Income | -$7.3M-33.5% | -$6.0M+80.8% | -$25.4M | -$31.5M-1708.1% | -$5.5M-859.9% | -$31.3M-39201.4% | N/A | -$1.7M |
| EBITDA | -$7.0M-48.8% | -$5.7M+81.5% | -$24.5M | -$30.7M-2306.9% | -$4.7M-719.8% | -$30.5M | N/A | -$1.3M |
| Interest Expense | $1.6M+31.9% | $2.1M+89.4% | $876K | $1.4M+935.7% | $1.2M+90353.8% | $1.1M+32493.5% | N/A | $138K |
| Net Income | -$18.4M-175.2% | -$7.7M+76.1% | -$27.9M | -$34.3M-1738.1% | -$6.7M-1061.8% | -$32.4M-38916.0% | N/A | -$1.9M |
| EPS (Basic) | -$7.13-32.0% | -$0.07+88.7% | -$0.25-150.0% | -$0.46-1050.0% | -$5.40-53900.0% | -$0.62 | -$0.10 | -$0.04 |
| EPS (Diluted) | -$7.13 | -$0.07 | -$0.25 | -$0.46 | -$5.40 | -$0.62 | -$0.10 | -$0.04 |
| Diluted Shares (Avg) | 3M | 105M | N/A | 74M | 1M | 52M+16.1% | N/A | 48M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
MEDS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.8M-39.6% | $30.1M-48.1% | $30.5M-46.9% | $52.8M | $54.2M | $58.1M | $57.3M+16844.1% | N/A |
| Current Assets | $5.6M-58.3% | $2.8M-83.3% | $2.8M-81.4% | $12.8M | $13.5M | $16.6M | $15.2M+4382.9% | N/A |
| Cash & Equivalents | $2.5M+484.9% | $52K-97.9% | $43K-95.9% | $4.2M | $420K | $2.5M | $1.0M+75291.2% | N/A |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Inventory | $1.5M-83.3% | $1.7M-82.4% | $1.6M-82.8% | $7.5M | $9.0M | $9.7M | $9.5M | N/A |
| Accounts Receivable | $1.2M-45.7% | $992K-64.9% | $1.1M-58.3% | $1.1M | $2.2M | $2.8M | $2.7M | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Goodwill | $14.2M-12.5% | $14.2M-12.5% | $14.2M-12.5% | $16.2M | $16.2M | $16.2M | $16.2M | N/A |
| Total Liabilities | $52.3M-2.0% | $45.2M-15.7% | $42.9M-15.2% | $46.0M | $53.3M | $53.6M | $50.6M+1462.3% | N/A |
| Current Liabilities | $39.4M-7.1% | $32.2M-30.3% | $29.8M-21.7% | $32.7M | $42.4M | $46.2M | $38.0M+1217.0% | N/A |
| Non-Current Liabilities | $12.8M+17.7% | $13.0M+76.5% | $13.1M+4.6% | $13.3M | $10.9M | $7.4M | $12.6M+3486.1% | N/A |
| Long-Term Debt | $12.6M+24.8% | $12.6M-47.8% | $12.6M+10.0% | $12.6M | $10.1M | $24.1M | $11.5M | N/A |
| Total Equity | -$19.5M-2254.6% | -$15.1M-436.3% | -$12.4M-284.8% | $6.8M-32.1% | $905K+128.8% | $4.5M+250.1% | $6.7M+332.2% | $10.0M |
| Retained Earnings | -$137.1M-180.7% | -$118.8M-181.5% | -$111.0M-1038.0% | -$83.2M | -$48.9M | -$42.2M | -$9.8M-236.3% | N/A |
MEDS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-39.2% | -$3.4M-153.3% | -$6.3M-139.9% | -$1.1M-209.4% | -$2.1M-730.1% | -$1.3M-4413.6% | -$2.6M | $1.0M |
| Depreciation & Amortization | $357K-55.6% | $357K-55.6% | $803K+24.0% | $803K+71.7% | $803K | $803K | $647K | $467K |
| Stock-Based Compensation | N/A | $1.4M-95.1% | N/A | $25.7M | $935K | $27.8M | N/A | N/A |
| Investing Cash Flow | -$242K-83.5% | -$205K+24.9% | -$255K-131.8% | -$221K+30.0% | -$132K | -$273K | $803K | -$316K |
| Financing Cash Flow | $5.5M+4748.6% | $3.6M+16.7% | $2.4M+14.9% | $5.2M+114198.3% | $114K+121.2% | $3.1M+1095.7% | $2.1M | $5K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MEDS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.2%+3.8pp | 10.9%+4.5pp | -470.2% | 7.7%-1.5pp | 6.5%+12.3pp | 6.4% | N/A | 9.2% |
| Operating Margin | -412.7% | -385.7% | -1517.5% | -1047.1% | -70.6% | -288.6% | N/A | -30.8% |
| Net Margin | -1031.7% | -496.5% | -1667.2% | -1139.0% | -85.6% | -298.5% | N/A | -32.9% |
| Return on Equity | N/A | N/A | N/A | -506.3%-487.6pp | -737.1% | -724.1% | N/A | -18.7% |
| Return on Assets | -56.0%-43.7pp | -25.7%+30.1pp | -91.4% | -65.0% | -12.3% | -55.9% | N/A | N/A |
| Current Ratio | 0.14-0.2x | 0.09-0.3x | 0.09-0.3x | 0.39 | 0.32 | 0.36 | 0.40+0.3x | N/A |
| Debt-to-Equity | N/A | N/A | N/A | 1.86 | 11.16 | 5.39 | 1.70 | N/A |
| Asset Turnover | 0.05-0.1x | 0.05-0.1x | 0.05 | 0.06 | 0.14 | 0.19 | N/A | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$12.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Datameds AI Inc Ranks
Frequently Asked Questions
What is Datameds AI Inc's annual revenue?
Datameds AI Inc (MEDS) reported $23.3M in total revenue for fiscal year 2025. This represents a 28.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Datameds AI Inc's revenue growing?
Datameds AI Inc (MEDS) revenue grew by 28.7% year-over-year, from $18.1M to $23.3M in fiscal year 2025.
Is Datameds AI Inc profitable?
No, Datameds AI Inc (MEDS) reported a net income of -$101.3M in fiscal year 2025.
What is Datameds AI Inc's EBITDA?
Datameds AI Inc (MEDS) had EBITDA of -$90.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Datameds AI Inc have?
As of fiscal year 2025, Datameds AI Inc (MEDS) had $43K in cash and equivalents against $12.6M in long-term debt.
What is Datameds AI Inc's gross margin?
Datameds AI Inc (MEDS) had a gross margin of -27.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Datameds AI Inc's operating cash flow?
Datameds AI Inc (MEDS) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Datameds AI Inc's total assets?
Datameds AI Inc (MEDS) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Datameds AI Inc's current ratio?
Datameds AI Inc (MEDS) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Datameds AI Inc's return on assets (ROA)?
Datameds AI Inc (MEDS) had a return on assets of -332.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Datameds AI Inc's P/E ratio?
Datameds AI Inc (MEDS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.9M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Datameds AI Inc's price-to-sales ratio?
Datameds AI Inc (MEDS) trades at 0.4x sales, its market capitalization divided by revenue of $8.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.9M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Datameds AI Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Datameds AI Inc (MEDS) held $43K in cash, cash equivalents and investments, and reported an operating cash outflow of $10.9M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Datameds AI Inc's debt-to-equity ratio negative or not reported?
Datameds AI Inc (MEDS) has negative shareholder equity of -$12.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Datameds AI Inc's Altman Z-Score?
Datameds AI Inc (MEDS) has an Altman Z-Score of -15.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Datameds AI Inc's Piotroski F-Score?
Datameds AI Inc (MEDS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Datameds AI Inc's earnings high quality?
Datameds AI Inc (MEDS) reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Datameds AI Inc cover its interest payments?
Datameds AI Inc (MEDS) reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Datameds AI Inc?
Datameds AI Inc (MEDS) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.